Article

Outpatient chemotherapy with S-1 for recurrent head and neck cancer.

Department of Otolaryngology-Head and Neck Surgery, National Defense Medical Collage, 3-2 Namiki, Tokorozawa, Saitama 359-8513, Japan.
Anticancer research (impact factor: 1.73). 03/2009; 29(2):577-81. pp.577-81
Source: PubMed

ABSTRACT This retrospective study evaluates the efficacy and safety of S-1 chemotherapy or S-1 followed by low-dose docetaxel chemotherapy for recurrent head and neck cancer.
S-1 was administered to 21 patients with recurrent head and neck cancer, in outpatient settings. Of these 21 patients, 8 were additionally administered a low dose of docetaxel fortnightly.
The survival rate of patients with squamous cell carcinoma of the head and neck was 59.1% for 12 months and 17.5% for 24 months, with a median survival time of 18 months. Time to progression of more than 12 months was shown by 4 patients (22.2%). Most adverse events were mild (up to grade 2).
S-1 therapy is considered a safe and effective treatment option. From the viewpoint of tumour dormancy, S-1 therapy is a useful vigorous anticancer treatment that can be provided while maintaining patients' quality of life in recurrent cases.

0 0
 · 
0 Bookmarks
 · 
25 Views
  • Source
    Article: Research Stereotactic radiosurgery may contribute to overall survival for patients with recurrent head and neck carcinoma
    Koji Kawaguchi, Kengo Sato, Akihisa Horie, Susumu Iketani, Hiroyuki Yamada, Yasunori Nakatani, Junichi Sato, Yoshiki Hamada
    [show abstract] [hide abstract]
    ABSTRACT: Background: The aim of this study is to examine the effect of stereotactic radiosurgery (SRS) in the treatment of advanced, recurrent lesions for head and neck carcinoma both with and without lymph node involvement. Methods: Between April 2006 and July 2007, 22 patients (mean age 67 years) with advanced, recurrent head and neck carcinoma were treated with stereotactic radiosurgery. All of the patients except one had biopsy confirmed disease prior to stereotactic radiosurgery. Patients included 3 rT2, 8 rT3, and 9 rT4; 8 of the patients had lymph node metastases. Marginal SRS doses were 20-42 Gy delivered in two to five fractions. Starting one month after SRS, all patients received S-1 oral chemotherapy for one year.
  • Source
    Article: Stereotactic radiosurgery may contribute to overall survival for patients with recurrent head and neck carcinoma.
    Koji Kawaguchi, Kengo Sato, Akihisa Horie, Susumu Iketani, Hiroyuki Yamada, Yasunori Nakatani, Junichi Sato, Yoshiki Hamada
    [show abstract] [hide abstract]
    ABSTRACT: The aim of this study is to examine the effect of stereotactic radiosurgery (SRS) in the treatment of advanced, recurrent lesions for head and neck carcinoma both with and without lymph node involvement. Between April 2006 and July 2007, 22 patients (mean age 67 years) with advanced, recurrent head and neck carcinoma were treated with stereotactic radiosurgery. All of the patients except one had biopsy confirmed disease prior to stereotactic radiosurgery. Patients included 3 rT2, 8 rT3, and 9 rT4; 8 of the patients had lymph node metastases. Marginal SRS doses were 20-42 Gy delivered in two to five fractions. Starting one month after SRS, all patients received S-1 oral chemotherapy for one year. At an overall median follow-up of 24 months (range, 4-39 months), for the 14 locally recurrent patients without lymph node metastases, 9 patients (64.3%) had a complete response (CR), 1 patient (7.1%) had a partial response (PR), 1 patient (7.1%) had stable disease (SD), and 3 patients (21.4%) had progressive disease (PD). For the 8 patients with lymph node metastases, 1 patient with a single retropharyngeal (12.5%) had CR; the remaining 7 patients (87.5%) all progressed. Nine patients have died from their cancer. The overall actuarial 2-year survival for the patients with and without lymph node metastases is 12.5% and 78.6%, respectively. These results show the benefit of stereotactic radiosurgery salvage treatment for advanced, recurrent lesions, without lymph node metastases in previously irradiated head and neck cancer.
    Radiation Oncology 01/2010; 5:51. · 2.32 Impact Factor
Data provided are for informational purposes only. Although carefully collected, accuracy cannot be guaranteed. The impact factor represents a rough estimation of the journal's impact factor and does not reflect the actual current impact factor. Publisher conditions are provided by RoMEO. Differing provisions from the publisher's actual policy or licence agreement may be applicable.

Keywords

12 months
 
18 months
 
21 patients
 
24 months
 
4 patients
 
adverse events
 
effective treatment option
 
grade 2
 
low dose
 
low-dose docetaxel chemotherapy
 
median survival time
 
patients' quality
 
recurrent cases
 
recurrent head
 
retrospective study
 
S-1 chemotherapy
 
S-1 therapy
 
survival rate
 
tumour dormancy
 
useful vigorous anticancer treatment
 

Taku Yamashita